Online first
Original article
Published online: 2024-10-08
Cardioprotective effect of Perakine against myocardial ischemia-reperfusion injury of type-2 diabetic rat in Langendorff-Perfused Rat Hearts: Role of TLR4/NF-kB signalling pathway
, 1
DOI: 10.5603/fm.101274
Pubmed: 39387397
Abstract
Myocardial ischemia-reperfusion (I/R) injury is a grave life-threatening situation, if not treated well in time. The development of natural remedies for myocardial I/R injury has witnessed dramatic growth in the last decade. Prompted by the above, in the present study, we have elucidated the pharmacological effect of Perakine (PER), an indole alkaloid in myocardial ischemia-reperfusion injury in type 2 diabetic rats. The model was established by inducing diabetes in experimental rats followed by the development of myocardial I/R injury model of isolated rat heart by the use of improved Langendorff retrograde perfusion technology. Results of the study suggest that PER significantly lowered the infarct size and infarct volume, and improvement in cardiac ability (LVSP, ±dP/dtmax, and heart rate). It also showed a significant lowering of cardiac biomarkers (CK, CK(MB), ALT, AST, and LDH) in a dose-dependent manner as compared to unprotected IR rats. The level of oxidative stress (MDA, SOD, and GSH) was also found lowered in IR rats together with a reduction in the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-17, and TNF-α). The anti-inflammatory acting of PER on IR rats is believed to be linked with the reduction of TNF-α, NF-κB, and TLR4 in both RT-qPCR and western blot analysis. Our research showed that Perakine could potentially alleviate cardiac ischemia-reperfusion injury in rats by blocking the TLR4/NF-κB signaling cascade.
Keywords: Indole alkaloidDiabetesInfarct sizecytokinesinflammation.
References
- Ahmed M, Qazzaz A, Khalaf DS. Ischemic heart disease treatment. IJRST. 2022; 12(01): 39–41.
- Aldous SJ. Cardiac biomarkers in acute myocardial infarction. Int J Cardiol. 2013; 164(3): 282–294.
- Alshehry ZH, Mundra PA, Barlow CK, et al. Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation. 2016; 134(21): 1637–1650.
- Ashraf M, Ullah H, Shah SF. Different risk factors for ischemic heart disease. PJMHS. 2021; 15(1).
- Brown JD, Lin CY, Duan Q, et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014; 56(2): 219–231.
- Butler MS, Robertson AAB, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 2014; 31(11): 1612–1661.
- Chang J, Nair V, Luk A, et al. Pathology of myocardial infarction. Diagnostic Histopathology. 2013; 19(1): 7–12.
- Choi D, Hwang KC, Lee KY, et al. Ischemic heart diseases: current treatments and future. J Control Release. 2009; 140(3): 194–202.
- Collinson P, Suvisaari J, Aakre KM, et al. EFLM Task Group on Cardiac Markers. How well do laboratories adhere to recommended guidelines for cardiac biomarkers management in europe? The cardiac marker guideline uptake in europe (CAMARGUE) study of the european federation of laboratory medicine task group on cardiac markers. Clin Chem. 2021; 67(8): 1144–1152.
- Cragg GM, Newman DJ, Snader KM, et al. The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J Nat Prod. 1993; 56(10): 1657–1668.
- Dhalla NS, Elmoselhi AB, Hata T, et al. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000; 47(3): 446–456.
- Fan D, Li Li, Li Z, et al. Effect of hyperlipidemia on the incidence of cardio-cerebrovascular events in patients with type 2 diabetes. Lipids Health Dis. 2018; 17(1): 102.
- Fengyang Li, Yunhe Fu, Bo L, et al. Stevioside suppressed inflammatory cytokine secretion by downregulation of NF-κB and MAPK signaling pathways in LPS-stimulated RAW264.7 cells. Inflammation. 2012; 35(5): 1669–1675.
- Di Filippo C, Cuzzocrea S, Rossi F, et al. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev. 2006; 24(2): 77–87.
- Frangogiannis NG. Pathophysiology of myocardial infarction. Compr Physiol. 2015; 5(4): 1841–1875.
- Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53(1): 31–47.
- Garg P, Morris P, Fazlanie AL, et al. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med. 2017; 12(2): 147–155.
- González-Robledo G, Jaramillo MJ, Comín-Colet J. Diabetes mellitus, insuficiencia cardiaca y enfermedad renal crónica. Revista Colombiana de Cardiología. 2020; 27: 3–6.
- Gupta A, Bhat H, Singh U. Discovery of imeglimin-inspired novel 1,3,5-triazine derivatives as antidiabetic agents in streptozotocin-induced diabetes in Wistar rats via inhibition of DPP-4. RSC Medicinal Chemistry. 2023; 14(8): 1512–1536.
- Gupta A, Bhat HR, Singh UP. Discovery of novel 1,3,5-triazine derivatives as an antidiabetic agent in Wistar rats via inhibition of DPP-4. Future Med Chem. 2023; 15(10): 829–852.
- Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008; 13(19-20): 894–901.
- Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013; 123(1): 92–100.
- Hobson MJ, Zingarelli B. Ischemia - reperfusion injury. In: Wheeler DS, Wong HR, Shanley TP. ed. Pediatric Critical Care Medicine: Volume 1: Care of the Critically Ill or Injured Child, 2nd ed. Springer, Berlin 2014: 251–268.
- Hu SS. The Writing Committee Of The Report On Cardiovascular Health And Diseases In China,. Report on cardiovascular health and diseases in China 2021: an updated summary. J Geriatr Cardiol. 2023; 20(6): 399–430.
- Jokerst JV, Cauwenberghs N, Kuznetsova T, et al. Circulating biomarkers to identify responders in cardiac cell therapy. Sci Rep. 2017; 7(1): 4419.
- Khan MAb, Hashim MJ, Mustafa H, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020; 12(7): e9349.
- Kumar S, Kumari D, Singh B. Genus Rauvolfia: A review of its ethnopharmacology, phytochemistry, quality control/quality assurance, pharmacological activities and clinical evidence. J Ethnopharmacol. 2022; 295: 115327.
- Study the level of some serum lipid profile parameters in patients with an ischemic heart disease. Tikrit J Pure Sci. 2023; 22(2): 43–47.
- Li W, Li W, Leng Y, et al. Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress. DNA Cell Biol. 2020; 39(2): 210–225.
- Meikle PJ, Wong G, Tsorotes D, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol. 2011; 31(11): 2723–2732.
- Melamed K, Goldhaber S. Inflammation and Myocardial Infarction. Circulation. 2014; 130(24).
- Ocampo-Salgado C, Palacio-Uribe J, Duque-Ramírez M, et al. Valor pronóstico de biomarcadores cardíacos en la enfermedad por COVID-19. Revista Colombiana de Cardiología. 2020; 27(3): 137–141.
- Pivato CA, Chandiramani R, Petrovic M, et al. Depression and ischemic heart disease. Int J Cardiol. 2022; 364: 9–15.
- Rahman A, Fazal F. Blocking NF-κB: an inflammatory issue. Proc Am Thorac Soc. 2011; 8(6): 497–503.
- Rosales PF, Bordin GS, Gower AE, et al. Indole alkaloids: 2012 until now, highlighting the new chemical structures and biological activities. Fitoterapia. 2020; 143: 104558.
- Seki A, Fishbein MC. Ischemic heart disease. Pathobiology of Human Disease. 2014: 995–1013.
- Severino P, D'Amato A, Pucci M, et al. Ischemic heart disease pathophysiology paradigms overview: from plaque activation to microvascular dysfunction. Int J Mol Sci. 2020; 21(21).
- Shen T, Xing G, Zhu J, et al. Effects of 12-week supplementation of a polyherbal formulation in old adults with prehypertension/hypertension: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2019; 2019: 7056872.
- Strelitz J, Ahern AL, Long GH, et al. Moderate weight change following diabetes diagnosis and 10 year incidence of cardiovascular disease and mortality. Diabetologia. 2019; 62(8): 1391–1402.
- Su X, Zhou M, Li Y, et al. Protective effects of natural products against myocardial ischemia/reperfusion: Mitochondria-targeted therapeutics. Biomed Pharmacother. 2022; 149: 112893.
- Suman S, Biswas A, Kohaf N, et al. The diabetes-heart disease connection: recent discoveries and implications. Curr Probl Cardiol. 2023; 48(11): 101923.
- Surekha RH, Srikanth BB, Jharna P, et al. Oxidative stress and total antioxidant status in myocardial infarction. Singapore Med J. 2007; 48(2): 137–142.
- Wang C, Zhu L, Yuan W, et al. Diabetes aggravates myocardial ischaemia reperfusion injury via activating Nox2‐related programmed cell death in an AMPK‐dependent manner. J Cell Mol Med. 2020; 24(12): 6670–6679.
- Wang D, Hu X, Lee SH, et al. Diabetes exacerbates myocardial ischemia/reperfusion injury by down-regulation of microrna and up-regulation of o-glcnacylation. JACC Basic Transl Sci. 2018; 3(3): 350–362.
- Wang HB, Liu XK. Novel indole alkaloid from the flowers of Rauvolfia yunnanensis. Gaodeng Xuexiao Huaxue Xuebao/Chemical Journal of Chinese Universities. 2010; 31(10).
- Yang T, Zhang D. Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. Ageing Res Rev. 2023; 86: 101884.
- Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003; 285(2): H579–H588.
